NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

LATAM(拉丁美洲)疼痛管理藥物市場:按藥物類別,適應症的區域市場機會分析和行業預測(2019-2027)

LATAM Pain Management Drugs Market by Drug Class,, Indication : Regional Opportunity Analysis and Industry Forecast, 2019-2027

出版商 Allied Market Research 商品編碼 975068
出版日期 內容資訊 英文 235 Pages
商品交期: 2-3個工作天內
價格
LATAM(拉丁美洲)疼痛管理藥物市場:按藥物類別,適應症的區域市場機會分析和行業預測(2019-2027) LATAM Pain Management Drugs Market by Drug Class,, Indication : Regional Opportunity Analysis and Industry Forecast, 2019-2027
出版日期: 2020年10月31日內容資訊: 英文 235 Pages
簡介

2019年,拉丁美洲疼痛管理市場價值268.382億美元,從2020年到2027年的複合年增長率為3.5%,到2027年有望將達到33.832億美元。

疼痛是由組織損傷或疾病引起的痛苦的感覺和情感感覺。此外,多種疾病也會引起不適,包括多發性硬化症,骨關節炎,胃潰瘍,慢性關節炎,纖維肌痛,糖尿病性神經病和癌症。

疼痛的時間長短不一,從短期急性疼痛到長期慢性疼痛。急性疼痛是突然疼痛的發作,而慢性疼痛則是由骨骼和關節老化,神經損傷或受傷引起的。疼痛管理涉及使用特定範圍的藥物減□□輕或治療疼痛。有些藥物可以通過多種生理機制緩解疼痛,包括靶向傷害感受器。

由於老年人往往患有關節痛和其他慢性病,因此老年人口的增長是拉美疼痛管理市場增長的主要動力。此外,諸如癌症,糖尿病性神經病和骨關節炎等慢性疾病的流行正在推動拉丁美洲的市場增長。此外,增加手術和提高醫療費用有望促進市場增長。但是,藥物濫用,處方鎮痛藥的到期以及鎮痛藥等替代品的出現正在抑制拉丁美洲的市場增長。拉丁美洲的疼痛管理藥物市場根據藥物類別,適應症和地區劃分。根據藥物類別,市場分為非甾體類抗炎藥(NSAIDs),麻醉藥,抗驚厥藥,抗腸胃痛藥,抗抑鬱藥,阿片類藥物和非藥物鎮痛藥。

根據適應症,市場是關節炎疼痛,神經病性疼痛,癌性疼痛,慢性背痛,術後疼痛,偏頭痛,纖維肌痛,骨折,肌肉挫傷,急性陰囊等巴西,阿根廷,哥倫比亞,秘魯,智利,厄瓜多爾,巴拿馬和其他拉丁美洲按地區進行了分析。

按藥物類別劃分,由於鴉片類藥物在緩解主要慢性疾病的痛苦方面具有很高的效率,因此鴉片類藥物在2019年對市場的貢獻最大。預計麻醉劑部分將在預測期內以最高速度增長。

跡象表明,神經源性疼痛細分市場將在2019年佔據主導地位,預計在預測期內將出現顯著增長。此外,患者人數的大量增長是該細分市場對藥物需求增長的主要因素。由於拉丁美洲的外科手術數量增加以及導致下背部疼痛的慢性病患病率增加,預計在整個預測期內,癌性和慢性下背部疼痛部分將以最高的速度增長。

巴西將在2019年主導市場佔有率,並有望在整個預測期內保持主導地位。這是由於許多老化和良好的監管條件。越來越多的藥物濫用和鴉片類藥物成癮減少了鴉片類藥物處方的使用,並減少了該地區用於疼痛管理的鴉片類藥物的消費。另一方面,預計阿根廷將在預測期內實現最高增長率,這主要是由於該地區存在更多的患者群體以及醫療保健費用增加。

本報告對拉丁美洲的止痛藥市場進行了調查,並按藥物類別/適應症/地區,市場趨勢,增長因素和抑制因素分析以及市場概述了市場,市場規模的趨勢和預測。它提供全面的信息,例如機會,競爭條件和主要公司的概況。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
    • 主要成功策略
  • 主要公司的定位
  • 波特對拉丁美洲的五種力量分析
  • 市場動態
    • 成長因素
      • 慢性病發病率增加
      • 有利的監管方案
      • 老年人口的增加
    • 抑制因素
      • 替代療法的可用性
      • 藥物濫用
      • 處方藥專利已過期
    • 市場機會
      • 藥物開發的進展
      • 新興經濟體的不發達市場
  • 拉丁美洲止痛藥的COVID-19效果分析
  • 拉丁美洲分子信息
    • 巴西
      • NSAID
      • 鴉片類藥物
    • 阿根廷
      • NSAID
      • 鴉片類藥物
    • 哥倫比亞
      • NSAID
      • 鴉片類藥物
    • 秘魯
      • NSAID
      • 鴉片類藥物
    • 智利
      • NSAID
      • 鴉片類藥物
    • 厄瓜多爾
      • NSAID
      • 鴉片類藥物
    • 巴拿馬
      • NSAID
      • 鴉片類藥物

第4章拉丁美洲疼痛管理藥物市場:按藥物類別

  • 概述
    • 市場規模和預測
  • NSAID
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 麻醉藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 抗驚厥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 抗近視藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 抗抑鬱藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 鴉片類藥物
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
  • 非藥物止痛藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家

第5章:拉丁美洲疼痛管理藥物市場:按適應症

  • 概述
    • 市場規模和預測
  • 關節炎疼痛
    • 市場規模和預測:按國家
  • 神經性疼痛
    • 市場規模和預測:按國家
  • 癌症疼痛
    • 市場規模和預測:按國家
  • 慢性背痛
    • 市場規模和預測:按國家
  • 術後疼痛
    • 市場規模和預測:按國家
  • 頭疼
    • 市場規模和預測:按國家
  • 纖維肌痛
    • 市場規模和預測:按國家
  • 骨折
    • 市場規模和預測:按國家
  • 肌肉挫傷/肌肉差異
    • 市場規模和預測:按國家
  • 急性蟲滴發炎
    • 市場規模和預測:按國家
  • 其他
    • 市場規模和預測:按國家

第6章拉丁美洲止痛藥市場:按國家

  • 概述
  • 拉丁美洲
    • 主要市場趨勢,增長因素和機遇
    • 拉丁美洲
      • 市場規模和預測:按國家
      • 市場規模和預測:按藥物類別
      • 市場規模和預測:按指示
      • 巴西
      • 阿根廷
      • 哥倫比亞
      • 秘魯
      • 智利
      • 厄瓜多爾
      • 巴拿馬
      • 其他拉丁美洲

第7章公司簡介

  • ABBOTT LABORATORIES
  • AXON PHARMA
  • ELI LILY AND COMPANY
  • GRUNENTHAL
  • GLAXOSMITHKLINE PLC (GSK)
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER INC.
  • SANOFI
目錄
Product Code: A07588

Title:
LATAM Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications): Regional Opportunity Analysis and Industry Forecast, 2019-2027.

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027.

Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available that provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the LATAM pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth in Latin America. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth in Latin America. The LATAM pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics.

On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. By region, it is analyzed across Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Panama, and rest of Latin America.

The key players operating in the LATAM pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Drug class segment review

By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

  • Segment review

By indication, the neuropathic pain segment accounted for a majority of the market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries in Latin America and rise in prevalence of chronic diseases that lead to back pain.

  • Brazil accounted for majority of the market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Argentina is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • The market forecast is studied from 2020 to 2027
  • Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain
  • Acute appendicitis
  • Others

By Region

  • LATAM
  • Brazil
  • Argentina
  • Colombia
  • Ecuador
  • Panama
  • Chile
  • Peru
  • Rest of Latin America

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Eli Lilly & Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV.
  • Novartis AG
  • Pfizer, Inc.
  • Axon
  • Sanofi
  • GRUNENTHAL
  • OTHER PROMINENT MARKET PLAYERS
  • Allergen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sorrento Therapeutics
  • Valeant Pharmaceuticals International Inc.
  • WEX Pharmaceuticals
  • Zynerba Pharmaceuticals.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning
  • 3.4.Porter's five force analysis for LATAM
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in incidences of chronic diseases
      • 3.5.1.2.Favorable regulatory scenario
      • 3.5.1.3.Increase in geriatric population
    • 3.5.2.Restraints
      • 3.5.2.1.Availability of alternative therapies
      • 3.5.2.2.Drug exploitation
      • 3.5.2.3.Patent expiration of prescription drugs
    • 3.5.3.Opportunities
      • 3.5.3.1.Advancements in drug development
      • 3.5.3.2.Untapped markets in developing economies
  • 3.6.COVID-19 impact analysis for LATAM Pain Management Drugs
  • 3.7.Molecule information for LATAM
    • 3.7.1.Brazil
      • 3.7.1.1.NSAIDs
      • 3.7.1.2.Opioids
    • 3.7.2.Argentina
      • 3.7.2.1.NSAIDs
      • 3.7.2.2.Opioids
    • 3.7.3.Colombia
      • 3.7.3.1.NSAIDs
      • 3.7.3.2.Opioids
    • 3.7.4.Peru
      • 3.7.4.1.NSAIDs
      • 3.7.4.2.Opioids
    • 3.7.5.Chile
      • 3.7.5.1.NSAIDs
      • 3.7.5.2.Opioids
    • 3.7.6.Ecuador
      • 3.7.6.1.NSAIDs
      • 3.7.6.2.Opioids
    • 3.7.7.Panama
      • 3.7.7.1.NSAIDs
      • 3.7.7.2.Opioids

CHAPTER 4:LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.NSAIDs
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by country
  • 4.3.Anesthetics
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by country
  • 4.4.Anticonvulsants
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by country
  • 4.5.Antimigraine drug
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by country
  • 4.6.Antidepressant drugs
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by country
  • 4.7.Opioids
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by country
  • 4.8.Non-narcotic analgesics
    • 4.8.1.Key market trends, growth factors, and opportunities
    • 4.8.2.Market size and forecast, by country

CHAPTER 5:LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Arthritic pain
    • 5.2.1.Market size and forecast, by country
  • 5.3.Neuropathic pain
    • 5.3.1.Market size and forecast, by country
  • 5.4.Cancer pain
    • 5.4.1.Market size and forecast, by country
  • 5.5.Chronic back pain
    • 5.5.1.Market size and forecast, by country
  • 5.6.Post-operative pain
    • 5.6.1.Market size and forecast, by country
  • 5.7.Migraine
    • 5.7.1.Market size and forecast, by country
  • 5.8.Fibromyalgia
    • 5.8.1.Market size and forecast, by country
  • 5.9.Bone fracture
    • 5.9.1.Market size and forecast, by country
  • 5.10.Muscle sprain/strain
    • 5.10.1.Market size and forecast, by country
  • 5.11.Acute appendicitis
    • 5.11.1.Market size and forecast, by country
  • 5.12.Others
    • 5.12.1.Market size and forecast, by country

CHAPTER 6:LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY

  • 6.1.Overview
  • 6.2.LATAM (Latin America)
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.LATAM (Latin America)
      • 6.2.2.1.Market size and forecast, by country
      • 6.2.2.2.Market size and forecast, by drug class
      • 6.2.2.3.Market size and forecast, by indication
      • 6.2.2.4.Brazil
      • 6.2.2.4.1.Market size and forecast, by drug class
      • 6.2.2.4.2.Market size and forecast, by indication
      • 6.2.2.5.Argentina
      • 6.2.2.5.1.Market size and forecast, by drug class
      • 6.2.2.5.2.Market size and forecast, by indication
      • 6.2.2.6.Colombia
      • 6.2.2.6.1.Market size and forecast, by drug class
      • 6.2.2.6.2.Market size and forecast, by indication
      • 6.2.2.7.Peru
      • 6.2.2.7.1.Market size and forecast, by drug class
      • 6.2.2.7.2.Market size and forecast, by indication
      • 6.2.2.8.Chile
      • 6.2.2.8.1.Market size and forecast, by drug class
      • 6.2.2.8.2.Market size and forecast, by indication
      • 6.2.2.9.Ecuador
      • 6.2.2.9.1.Market size and forecast, by drug class
      • 6.2.2.9.2.Market size and forecast, by indication
      • 6.2.2.10.Panama
      • 6.2.2.10.1.Market size and forecast, by drug class
      • 6.2.2.10.2.Market size and forecast, by indication
      • 6.2.2.11.Rest of Latin America
      • 6.2.2.11.1.Market size and forecast, by drug class
      • 6.2.2.11.2.Market size and forecast, by indication

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBOTT LABORATORIES
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
  • 7.2.AXON PHARMA
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Product portfolio
  • 7.3.ELI LILY AND COMPANY
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
    • 7.3.6.Key strategic moves and developments
  • 7.4.GRUNENTHAL
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Product portfolio
    • 7.4.4.Business performance
    • 7.4.5.Key strategic moves and developments
  • 7.5.GLAXOSMITHKLINE PLC (GSK)
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.JOHNSON & JOHNSON
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.MERCK & CO., INC.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.MYLAN N.V.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.NOVARTIS INTERNATIONAL AG
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
    • 7.9.6.Key strategic moves and developments
  • 7.10.PFIZER INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and developments
  • 7.11.SANOFI
    • 7.11.1.Company overview
    • 7.11.2.Company snapshot
    • 7.11.3.Operating business segments
    • 7.11.4.Product portfolio
    • 7.11.5.Business performance

LIST OF TABLES

  • TABLE 01.BRAZIL NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 02.BRAZIL OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 03.ARGENTINA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 04.ARGENTINA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 05.COLOMBIA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 06.COLOMBIA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 07.PERU NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 08.PERU OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 09.CHILE NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 10.CHILE OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 11.ECUADOR NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 12.ECUADOR OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 13.PANAMA NSAIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 14.PANAMA OPIOIDS MARKET, BY MOLECULE, 2019, ($MILLION)
  • TABLE 15.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 16.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 17.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 18.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 19.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETICS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 20.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETICS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 21.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANTS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 22.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANTS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 23.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE AGENTS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 24.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE AGENTS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 25.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANTS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 26.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANTS, BY COUNTRY, 2019-2027 (MILLION UNITS)S
  • TABLE 27.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 28.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 29.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 30.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESIC, BY COUNTRY, 2019-2027 (MILLION UNITS)S
  • TABLE 31.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 32.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)S
  • TABLE 33.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ARTHRITIC PAIN, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 34.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ARTHRITIC PAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 35.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY COUNTRY, 2019-2027 ($MILLION)S
  • TABLE 36.LATAM PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 37.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 38.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 39.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 40.LATAM PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 41.LATAM PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 42.LATAM PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 43.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 44.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 45.LATAM PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 46.LATAM PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 47.LATAM PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 48.LATAM PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 49.LATAM PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN/STRAIN, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 50.LATAM PAIN MANAGEMENT DRUGS MARKET, BY SPRAIN/STRAIN, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 51.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 52.LATAM PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 53.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 54.LATAM PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 55.LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 56.LATAM PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 57.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 58.LATAM PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 59.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 60.LATAM PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 62.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 63.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 64.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 65.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 66.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 67.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 68.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 69.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 70.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 71.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 72.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 73.PERU PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 74.PERU PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 75.PERU PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 76.PERU PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 77.CHILE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 78.CHILE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 79.CHILE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 80.CHILE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 81.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 82.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 83.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 84.ECUADOR PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 85.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 86.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 87.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 88.PANAMA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 89.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 90.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 (MILLION UNITS)
  • TABLE 91.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 92.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 (MILLION UNITS)
  • TABLE 93.ABBOTT: COMPANY SNAPSHOT
  • TABLE 94.ABBOTT: OERATING SEGMENT
  • TABLE 95.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 96.AXON PHARMA: COMPANY SNAPSHOT
  • TABLE 97.AXON PHARMA: PRODUCT PORTFOLIO
  • TABLE 98.ELI LILLY: COMPANY SNAPSHOT
  • TABLE 99.LILLY: OPERATING SEGMENTS
  • TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102.GRUNENTHAL: COMPANY SNAPSHOT
  • TABLE 103.GRUNENTHAL: PRODUCT PORTFOLIO
  • TABLE 104.GSK: COMPANY SNAPSHOT
  • TABLE 105.GSK: OPERATING SEGMENTS
  • TABLE 106.GSK: PRODUCT PORTFOLIO
  • TABLE 107.J&J: COMPANY SNAPSHOT
  • TABLE 108.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 109.J&J: PRODUCT PORTFOLIO
  • TABLE 110.MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 111.MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 112.MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 113.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114.MYLAN: COMPANY SNAPSHOT
  • TABLE 115.MYLAN: OPERATING BUSINESS SEGMENTS
  • TABLE 116.MYLAN: PRODUCT PORTFOLIO
  • TABLE 117.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 118.NOVARTIS: OPERATING SEGMENTS
  • TABLE 119.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 120.PFIZER: COMPANY SNAPSHOT
  • TABLE 121.PFIZER: OERATING SEGMENT
  • TABLE 122.PFIZER: PRODUCT PORTFOLIO
  • TABLE 123.SANOFI: COMPANY SNAPSHOSST
  • TABLE 124.SANOFI: OPERATING SEGMENTS
  • TABLE 125.SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.LATAM PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, 2017-2020
  • FIGURE 03.TOP WINNING STRATEGIES: BY DEVELOPMENT , 2017-2020
  • FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017-2020
  • FIGURE 05.TOP PLAYER POSTIONING, 2019
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTESS
  • FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
  • FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.LATAM PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 13.BRAZIL PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 14.ARGENTINA PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 15.COLOMBIA PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 16.PERU PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 17.CHILE PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 18.ECUADOR PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 19.PANAMA PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 20.REST OF LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET, 2020-2027 ($MILLION)
  • FIGURE 21.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 22.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 23.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 24.ELI LILLY: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 25.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 26.GRUNENTHAL: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 27.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 28.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 29.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 30.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 31.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 32.J&J: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 33.MERCK & CO., INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 34.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 35.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 36.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 37.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 38.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 39.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 40.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 41.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 42.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 43.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 44.SANOFI: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 45.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 46.SANOFI: REVENUE SHARE, BY REGION, 2019 (%)